BACKGROUND: This study assesses proof of concept and safety of a novel bio-inspired artificial pancreas (BiAP) system in adults with type 1 diabetes during fasting, overnight, and postprandial conditions. In contrast to existing glucose controllers in artificial pancreas systems, the BiAP uses a control algorithm based on a mathematical model of β-cell physiology. The algorithm is implemented on a miniature silicon microchip within a portable hand-held device that interfaces the components of the artificial pancreas. MATERIALS AND METHODS: In this nonrandomized open-label study each subject attended for a 6-h fasting study followed by a 13-h overnight and post-breakfast study on a separate occasion. During both study sessions the BiAP system was used, and microboluses of insulin were recommended every 5 min by the control algorithm according to subcutaneous sensor glucose levels. The primary outcome was percentage time spent in the glucose target range (3.9-10.0 mmol/L). RESULTS: Twenty subjects (55% male; mean [SD] age, 44 [10] years; duration of diabetes, 22 [12] years; glycosylated hemoglobin, 7.4% [0.7%] [57 (7) mmol/mol]; body mass index, 25 [4] kg/m(2)) participated in the fasting study, and the median (interquartile range) percentage time in target range was 98.0% (90.8-100.0%). Seventeen of these subjects then participated in the overnight/postprandial study, where 70.7% (63.9-77.4%) of time was spent in the target range and, reassuringly, 0.0% (0.0-2.3%) of time was spent in hypoglycemia (<3.9 mmol/L). CONCLUSIONS: The BiAP achieves safe glycemic control during fasting, overnight, and postprandial conditions.
BACKGROUND: This study assesses proof of concept and safety of a novel bio-inspired artificial pancreas (BiAP) system in adults with type 1 diabetes during fasting, overnight, and postprandial conditions. In contrast to existing glucose controllers in artificial pancreas systems, the BiAP uses a control algorithm based on a mathematical model of β-cell physiology. The algorithm is implemented on a miniature silicon microchip within a portable hand-held device that interfaces the components of the artificial pancreas. MATERIALS AND METHODS: In this nonrandomized open-label study each subject attended for a 6-h fasting study followed by a 13-h overnight and post-breakfast study on a separate occasion. During both study sessions the BiAP system was used, and microboluses of insulin were recommended every 5 min by the control algorithm according to subcutaneous sensor glucose levels. The primary outcome was percentage time spent in the glucose target range (3.9-10.0 mmol/L). RESULTS: Twenty subjects (55% male; mean [SD] age, 44 [10] years; duration of diabetes, 22 [12] years; glycosylated hemoglobin, 7.4% [0.7%] [57 (7) mmol/mol]; body mass index, 25 [4] kg/m(2)) participated in the fasting study, and the median (interquartile range) percentage time in target range was 98.0% (90.8-100.0%). Seventeen of these subjects then participated in the overnight/postprandial study, where 70.7% (63.9-77.4%) of time was spent in the target range and, reassuringly, 0.0% (0.0-2.3%) of time was spent in hypoglycemia (<3.9 mmol/L). CONCLUSIONS: The BiAP achieves safe glycemic control during fasting, overnight, and postprandial conditions.
Authors: Boris Kovatchev; Claudio Cobelli; Eric Renard; Stacey Anderson; Marc Breton; Stephen Patek; William Clarke; Daniela Bruttomesso; Alberto Maran; Silvana Costa; Angelo Avogaro; Chiara Dalla Man; Andrea Facchinetti; Lalo Magni; Giuseppe De Nicolao; Jerome Place; Anne Farret Journal: J Diabetes Sci Technol Date: 2010-11-01
Authors: Nathan R Hill; Nick S Oliver; Pratik Choudhary; Jonathan C Levy; Peter Hindmarsh; David R Matthews Journal: Diabetes Technol Ther Date: 2011-06-29 Impact factor: 6.118
Authors: H C Schaller; L Schaupp; M Bodenlenz; M E Wilinska; L J Chassin; P Wach; T Vering; R Hovorka; T R Pieber Journal: Diabet Med Date: 2006-01 Impact factor: 4.359
Authors: Boris P Kovatchev; Eric Renard; Claudio Cobelli; Howard C Zisser; Patrick Keith-Hynes; Stacey M Anderson; Sue A Brown; Daniel R Chernavvsky; Marc D Breton; Anne Farret; Marie-Josée Pelletier; Jérôme Place; Daniela Bruttomesso; Simone Del Favero; Roberto Visentin; Alessio Filippi; Rachele Scotton; Angelo Avogaro; Francis J Doyle Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Daniela Elleri; Janet M Allen; Kavita Kumareswaran; Lalantha Leelarathna; Marianna Nodale; Karen Caldwell; Peiyao Cheng; Craig Kollman; Ahmad Haidar; Helen R Murphy; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger; Roman Hovorka Journal: Diabetes Care Date: 2012-11-27 Impact factor: 19.112
Authors: Eyal Dassau; Howard Zisser; Rebecca A Harvey; Matthew W Percival; Benyamin Grosman; Wendy Bevier; Eran Atlas; Shahar Miller; Revital Nimri; Lois Jovanovic; Francis J Doyle Journal: Diabetes Care Date: 2012-11-27 Impact factor: 19.112
Authors: Lauren M Huyett; Trang T Ly; Gregory P Forlenza; Suzette Reuschel-DiVirgilio; Laurel H Messer; R Paul Wadwa; Ravi Gondhalekar; Francis J Doyle; Jordan E Pinsker; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Technol Ther Date: 2017-05-01 Impact factor: 6.118
Authors: Monika Reddy; Pau Herrero; Mohamed El Sharkawy; Peter Pesl; Narvada Jugnee; Darrell Pavitt; Ian F Godsland; George Alberti; Christofer Toumazou; Desmond G Johnston; Pantelis Georgiou; Nick S Oliver Journal: J Diabetes Sci Technol Date: 2015-11-17